Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3323440/
https://ncbi.nlm.nih.gov/pubmed/22390313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items